Clearmind Medicine (CMND) announced the initiation of its U.S. clinical trial site at the Yale School of Medicine’s Department of Psychiatry. With this initiation, the Company has now activated all planned sites for its clinical trial for its Phase I/IIa clinical trial in Alcohol Use Disorder, AUD, and can begin patient enrollment .Clearmind has completed all necessary preparations for the clinical trial, including obtaining Investigational New Drug, IND, approval from the U.S. Food and Drug Administration, FDA, to start the Phase I/IIa clinical trial, Institutional Review Board, IRB, approvals from each clinical site, launch of its Electronic Data Capture, EDC, system to support the clinical trial and the arrival of its drug candidate, CMND-100, into the United States following successful manufacturing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: MindMed announces dosing in Phase 3 Emerge study
- Clearmind Medicine receives notice of allowance for U.S. patent
- Clearmind Medicine launches first U.S. clinical site for AUD trial
- Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
- Clearmind Medicine announces U.S. clinical site initiation for CMND-100 trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue